Impaired migration and metastatic spread of human melanoma by a novel small molecule targeting the transmembrane domain of death receptor p75NTR
Lopes-Rodrigues, V.; Nyantakyi, S. A.; Lun, X.; Zhang, J.; Ramanujuan, A.; Salim, S.; Saleeb, M.; Senger, D. L.; Ibanez, C. F.
Show abstract
Receptor transmembrane domains (TMDs) are crucially involved in relaying ligand information from extracellular to intracellular spaces and represent attractive targets for small molecule manipulation of receptor function. Screening a library of over 8,000 drug-like compounds with an assay based on the TMD of death receptor p75NTR, we identified a novel small molecule capable of inhibiting p75NTR-mediated migration of human melanoma cells. Employing medicinal chemistry, a more potent derivative termed Np75-4A22 was identified that blocks nerve growth factor (NGF)-mediated melanoma invasion at submicromolar concentrations. Mechanistically, Np75-4A22 was found, at least in part, to function by antagonizing NGF-mediated recruitment of the actin-bundling protein fascin to p75NTR and its association with the actin cytoskeleton. Importantly, preclinical assessment of Np75-4A22 showed high oral bioavailability, low toxicity, and significant inhibition of melanoma lung metastases in a highly metastatic mouse model. These results support further development of this approach as an alternative or complementary strategy for patients that do not respond to conventional chemotherapy or immune checkpoint inhibitors.
Matching journals
The top 10 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Epithelial-mesenchymal transition sensitizes breast cancer cells to cell death via the fungus-derived sesterterpenoid ophiobolin A 96%
- PKIS Deep Dive Yields a Chemical Starting Point for Dark Kinases and a Cell Active BRSK2 Inhibitor 95%
- A screen of FDA-approved drugs identifies inhibitors of Protein Tyrosine Phosphatase 4A3 (PTP4A3 or PRL-3) 95%
Similar papers in this journal
- An Enzymatic TMPRSS2 Assay for Assessment of Clinical Candidates and Discovery of Inhibitors as Potential Treatment of COVID-19 95%
- Allosteric binders of ACE2 are promising anti-SARS-CoV-2 agents 94%
- Target-driven design of a coumarinyl chalcone scaffold based novel EF2 Kinase inhibitor suppresses breast cancer growth in vivo 94%
Similar papers in this journal
- Discovery of First-in-Class PROTAC Degraders of SARS-CoV-2 Main Protease 96%
- Development of potent and selective CK1α Molecular Glue Degraders 96%
- Discovery of CD28-Targeted Small Molecule Inhibitors of T Cell Co-stimulation Using Affinity Selection-Mass Spectrometry (AS-MS) and Ex Vivo Validation 95%
Similar papers in this journal
- Development of FERM domain protein-protein interaction inhibitors for MSN and CD44 as a potential therapeutic strategy for Alzheimer's disease. 95%
- Development of a novel high-throughput screen for the identification of new inhibitors of protein S-acylation 94%
- Covalent inhibition of the SARS-CoV-2 NiRAN domain via an active-site cysteine 94%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.